ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer

Molecular Cancer Therapeutics

Volumn 10, Issue 10, 2011, Pages 1876-1885

  Campbell, Nicole ^a   Greenaway, James ^a   Henkin, Jack ^b,c   Petrik, Jim ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b ABBOTT LABORATORIES   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOSPONDIN 1; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER EPIDEMIOLOGY; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SURVIVAL; TUMOR REGRESSION;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; ENDOTHELIAL CELLS; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGOPEPTIDES; OVARIAN NEOPLASMS; SURVIVAL RATE;

EID: 80053963249     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0402     Document Type: Article

References (47)

1. Harries M, Gore M. Part I: Chemotherapy for epithelial ovarian cancertreatment at first diagnosis. Lancet Oncol 2002;3:529-36.
2. Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2010;108:521-8.
3. Perez RP, Hamilton TC, Ozols RF. Resistance to alkylating agents and cisplatin: Insights from ovarian carcinoma model systems. Pharmacol Ther 1990;48:19-27.
4. Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 2010;76:1221-7.
5. Zabrenetzky V, Harris CC, Steeg PS, Roberts DD. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 1994;59:191-5.
6. Sanchez-Munoz A, Perez-Ruiz E, Mendiola Fernandez C, Alba Conejo E, Gonzalez-Martin A. Current status of anti-angiogenic agents in the treatment of ovarian carcinoma. Clin Transl Oncol 2010;11:589-95.
7. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
8. Campbell NE, Greenaway J, Henkin J, Moorehead RA, Petrik J. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia 2010;12:275-83.
9. Primo L, Ferrandi C, Roca C, Marchio S, di Blasio L, Alessio M, et al. Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB J 2005;19:1713-5.
10. Sun J, Hopkins BD, Tsujikawa K, Perruzzi C, Adini I, Swerlick R, et al. Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. Am J Physiol Heart Circ Physiol 2009;296:H1344-51.
11. Greenaway J, Henkin J, Lawler J, Moorehead R, Petrik J. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther 2009;8:64-74.
12. Baker LH, Rowinsky EK, Mendelson D, Humerickhouse RA, Knight RA, Qian J, et al. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 2008;26:5583-8.
13. Gordon MS, Mendelson D, Carr R, Knight RA, Humerickhouse RA, Iannone M, et al. A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer J 2008;113:3420-9.
14. Greenaway J, Moorehead R, Shaw P, Petrik J. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity ina mouse model of human epithelial ovarian cancer. Gynecol Oncol 2008;108:385-94.
15. Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 2005;10:382-91.
16. Burger RA. Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies. J Gynecol Oncol 2010;21:3-11.
17. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010;117:497-504.
18. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6.
19. Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, et al. Three distinct d-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 1999;55:332-8.
20. Ren B, Song K, Parangi S, Jin T, Ye M, Humphreys R, et al. A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res 2009;69:3856-65.
21. Zhang X, Connolly C, Duquette M, Lawler J, Parangi S. Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. Cancer Lett 2007;247:143-9.
22. Zhang X, Galardi E, Duquette M, Lawler J, Parangi S. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res 2005;11:5622-30.
23. Anderson JC, Grammer JR, Wang W, Nabors LB, Henkin J, Stewart JE Jr., et al. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther 2007;6:454-62.
24. Hasina R, Martin LE, Kasza K, Jones CL, Jalil A, Lingen MW. ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis. Cancer Prevention Res 2009;2:385-93.
25. Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, et al. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 2007;13:6689-95.
26. Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, et al. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 2007;30:303-9.
27. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10.
28. Nguyen HN, Averette HE, Hoskins W, Sevin BU, Penalver M, Steren A. National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 2010;72:3007-11.
29. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95:S161-92.
30. Garside SA, Henkin J, Morris KD, Norvell SM, Thomas FH, Fraser HM. A thrombospondin-mimetic peptide, ABT-898, suppresses angiogenesis and promotes follicular atresia in pre- and early-antral follicles in vivo. Endocrinology 2010;151:5905-15.
31. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Journal of Controlled Release 1998;53:49-67.
32. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:387-9.
33. Rege TA, Stewart JE Jr, Dranka B, Benveniste EN, Silverstein RL, Gladson CL. Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1. J Cell Physiol 2009;218:94-103.
34. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 2004;64:1570-4.
35. Nor JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 2010;37:209-18.
36. Bruel A, Touhami-Carrier M, Thomaidis A, Legrand C. Thrombospondin-1 (TSP-1) and TSP-1-derived heparin-binding peptides induce promyelocytic leukemia cell differentiation and apoptosis. Anticancer Res 2005;25:757-64.
37. Li K, Yang M, Yuen PM, Chik KW, Li CK, Shing MM, et al. Thrombospondin-1 induces apoptosis in primary leukemia and cell lines mediated by CD36 and Caspase-3. Int J Mol Med 2003;12:995-1001.
38. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 2010;17:206-25.
39. Wu J, Long Q, Xu S, Padhani AR. Study of tumor blood perfusion and its variation due to vascular normalization by anti-angiogenic therapy based on 3D angiogenic microvasculature. J Biomech 2009;42:712-21.
40. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008;8:790-7.
41. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
42. Tan DS, Agarwal R, Kave SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 2006;7:925-34.
43. Gadducci A, Viacava P, Cosio S, Cecchetti D, Fanelli G, Fanucchi A, et al. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer Res 2003;23:3001-8.
44. Fujimoto J, Sakaguchi H, Aoki I, Khatun S, Tamaya T. Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Br J Cancer 2001;85:313-6.
45. Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997;76:1221-7.
46. Behzadian MA, Windsor LJ, Ghaly N, Liou G, Tsai Nt, Caldwell RB. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 2003;17:752-4.
47. Senger DR, Galli SJ, Dvorak AM, Perruzzi C, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.